Table 3.

Impact of subclinical atherosclerosis and of BNP and CRP levels on the association of LDL group with incident CVD

	LDL group	LDL treatment	HR (95% CI)*	HR (95% CI)†	Change in HR‡	HR (95% CI)§	Change in HR¶
1	<100 mg/dL	No	1.00 (referent)	1.00 (referent)		1.00 (referent)
2	≥100 to <130 mg/dL	No	1.34 (0.99 to 1.81)	1.34 (0.99 to 1.81)	0.0% decrease	1.35 (1.00 to 1.83)	0.1% increase
3	<130 mg/dL	Yes	1.57 (1.07 to 2.31)	1.50 (1.02 to 2.20)	4.5% decrease	1.55 (1.05 to 2.28)	1.3% decrease
4	≥130 mg/dL	No	1.44 (1.08 to 1.93)	1.39 (1.04 to 1.86)	3.5% decrease	1.42 (1.06 to 1.91)	1.4% decrease
5	≥130 mg/dL	Yes	1.51 (0.98 to 2.32)	1.43 (0.93 to 2.20)	5.3% decrease	1.41 (0.92 to 2.17)	6.6% decrease

Analyses were conducted in a subsample with available information on carotid ultrasound abnormality, BNP and CRP (n=2811).

*HRs are adjusted for age, sex, systolic blood pressure, antihypertensive medication, smoking and diabetes mellitus. Note: HRs are slightly different from figure 3 due to differences in sample size.

†Multivariable model additionally adjusted for the presence versus absence of carotid ultrasound abnormality.

‡Change in the HR on additional adjustment for the presence of carotid ultrasound abnormality compared with the HR adjusted for only age, sex, systolic blood pressure, antihypertensive medication, smoking and diabetes mellitus.

§Multivariable model additionally adjusted for the presence versus absence of carotid ultrasound abnormality+adjustment for ln(BNP) and ln(CRP).

¶Change in the HR on additional adjustment for the presence of carotid ultrasound abnormality+ln(BNP)+ln(CRP) compared with the HR adjusted for only age, sex, systolic blood pressure, antihypertensive medication, smoking and diabetes mellitus.

BNP, B-type natriuretic peptide; CVD, cardiovascular disease; CRP, C reactive protein; LDL, low-density lipoprotein.